Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021
April 08 2021 - 6:30AM
Heidelberg, Germany, April 8, 2021 – Affimed
N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, announced today that it will release full year 2020 results
and corporate update on Thursday, April 15, 2021. The Company will
host a conference call at 8:30 a.m. Eastern Daylight Time.
The conference call will be available via phone and webcast. To
access the call, please dial +1-646-741-3167 for U.S. callers, or
+44 (0) 2071 928338 for international callers, and reference
conference ID 4271307 approximately 15 minutes prior to the
call.
To access the live audio webcast of the conference call please
visit the “Investors” section of the company’s website at
https://www.affimed.com/investors/webcasts_cp/. A replay of the
call will be archived on the Affimed website for 30 days after the
call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to give patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alex FudukidisHead of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024